My Treatment Approach: Advanced Ovarian Cancer

home / publications / supplements / my-treatment-approach-advanced-ovarian-cancer

The My Treatment Approach: Advanced Ovarian Cancer publication covers some of the latest practice-changing advances in the treatment for patients with advanced ovarian cancer following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.


Thomas C. Krivak, MD, of Allegheny Health Network

BRCA, HRD Testing Are Essential in Up-front Advanced Ovarian Cancer Management

Caroline Seymour
February 15th 2022
Article

Thomas C. Krivak, MD, discusses his approach to up-front treatment for women with newly diagnosed advanced ovarian cancer.

Angela Jain, MD

Frequent Blood Count Monitoring and Increased Physicality Are Important in PARP-Treated Ovarian Cancer

Caroline Seymour
February 2nd 2022
Article

Angela Jain, MD, provides perspective on use of PARP inhibitors in the treatment of patients with advanced ovarian cancer.

Richard Penson, MD, MBBS, of Massachusetts General Hospital

Penson Provides a Snapshot View of Switch Maintenance Therapy Selection in Recurrent Ovarian Cancer

Jessica Hergert
January 4th 2022
Article

Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.

Anil K. Sood, MD

HRD Status Drives Decisions With Frontline PARP Inhibition in Advanced Ovarian Cancer

Caroline Seymour
January 4th 2022
Article

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

Anil K. Sood, MD

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

Anil K. Sood, MD
December 17th 2021
Video

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Richard T. Penson, MD, MRCP

Dr. Penson on PARP Inhibitors as Switch Maintenance Therapy in Recurrent Ovarian Cancer

Richard T. Penson, MD, MRCP
December 17th 2021
Video

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.